Drug Trial Radar · NCT00729651
Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)
Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
343
Actual
Start
Mar 20, 2008
Primary completion
Apr 10, 2009
Study completion Apr 10, 2009
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Aug 7, 2008
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate the efficacy/safety of Fosamax Plus D
Conditions
- Osteoporosis Postmenopausal
Interventions
alendronate sodium (+) cholecalciferolDrug
Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
Comparator: Alendronate sodium (Fosamax)Drug
Alendronate sodium; tablet, once weekly, for 16 weeks
Comparator: CalciumDietary supplement
500 mg oral tablet calcium once daily, for 16 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients With Serum 25 OHD (Serum 25-hydroxyvitamin D) Below the Deficiency Level (Less Than 15 ng/ml) at 16 Weeks of TreatmentTime frame: 16 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.